Quick Answer
Eledon Pharmaceuticals, Inc. reported Net Income Loss of -$45.62 million for the year ending 2025.
- Eledon Pharmaceuticals, Inc. showed a decrease of -26.1% in Net Income Loss from 2024 to 2025.
- This data is from Eledon Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), Eledon Pharmaceuticals, Inc.'s Net Income Loss has declined by 372.8%.
- Historical annual values: Fiscal year 2025: -$45.62 million | Fiscal year 2024: -$36.18 million | Fiscal year 2023: -$116.54 million | Fiscal year 2022: -$87.97 million | Fiscal year 2021: -$34.51 million | Fiscal year 2020: -$22.81 million | Fiscal year 2019: -$16.01 million | Fiscal year 2018: -$14.07 million | Fiscal year 2017: -$13.12 million | Fiscal year 2016: -$5.66 million | Fiscal year 2015: -$45.09 million | Fiscal year 2014: -$23.30 million | Fiscal year 2013: -$15.73 million | Fiscal year 2012: -$9.65 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: